e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Treatment of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Anti-inflammatory activity of Erespal (Fenspirid, Servie, France) in COPD patients
E. Bukreeva, S. Nesterovich, O. Akbasheva, G. Seitova, T. Melnik, E. Dementieva (Tomsk, Russian Federation)
Source:
Annual Congress 2007 - Treatment of COPD
Session:
Treatment of COPD
Session type:
Thematic Poster Session
Number:
592
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Bukreeva, S. Nesterovich, O. Akbasheva, G. Seitova, T. Melnik, E. Dementieva (Tomsk, Russian Federation). Anti-inflammatory activity of Erespal (Fenspirid, Servie, France) in COPD patients. Eur Respir J 2007; 30: Suppl. 51, 592
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
A 12-year-old male child with fever, productive cough and sudden onset paralysis
Related content which might interest you:
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Is hyaluronic acid (HA) a marker of effectiveness of anti-inflammatory therapy in COPD patients?
Source: Annual Congress 2013 –COPD: markers and inflammation
Year: 2013
Effect of short-acting bronchodilators (BDs) on the severity of respiratory muscle (RM) strength in COPD patients (pts)
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Changes in drug prescription for asthma (A) and COPD (C) by GPs in Italy
Source: Annual Congress 2010 - Pharmacological treatment in primary care
Year: 2010
Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Are we missing asthma COPD overlap (ACO) diagnosis among patient with COPD?Alameeri Amel(1), Dudina Alexandra(1) , Stephen Lane(1), Kennedy Merian(2)
Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification
Year: 2019
Long term oxygen therapy (LTOT) prescription in chronic obstructive pulmonary disease (COPD) patients in Wigan (northwest England)
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012
The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Influence of bacterial colonization (BC) on the level of systemic inflammatory markers (SIM) in COPD patients (pts)
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014
Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE)
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
The impact of antimicrobial resistance on the cost-effectiveness of empirical treatment of community-acquired pneumonia (CAP) in France (FR), Belgium (BE) and Germany (DE)
Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication
Year: 2007
Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD)
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept